Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06WQT
|
|||
| Former ID |
DIB011897
|
|||
| Drug Name |
Nolatrexed
|
|||
| Synonyms |
Thymitaq; AG-337; ZX-337; Nolatrexed (intravenous), EXIMIAS
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 3 | [1] | |
| Company |
Agouron Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12N4OS
|
|||
| Canonical SMILES |
CC1=C(C2=C(C=C1)N=C(NC2=O)N)SC3=CC=NC=C3
|
|||
| InChI |
1S/C14H12N4OS/c1-8-2-3-10-11(13(19)18-14(15)17-10)12(8)20-9-4-6-16-7-5-9/h2-7H,1H3,(H3,15,17,18,19)
|
|||
| InChIKey |
XHWRWCSCBDLOLM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 147149-76-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00012324) Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer. U.S. National Institutes of Health. | |||
| REF 2 | A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.